Strategists Dismiss Nasdaq, Nikkei Wobbles
at The Street - 26 mins ago
Wobbles in the Nasdaq this year are not a 'canary in the coalmine' for a broader pullback in markets, strategists say, pointing to the concentrated nature of weakness in tech and biotech stocks.
Should You Invest in Gilead Sciences, Inc. Today?
Mark Reeth, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Shares of biopharma giant Gilead Sciences were up today after it announced a strong quarter, which included revenue doubling to $5 billion and earnings per share tripling from $0.43 to $1.33. Most of the company's strength this quarter came...
Most active Nasdaq-traded stocks
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.
Stocks Slip on Deep Drop in U.S. Home Sales
at The Street - Wed Apr 23, 3:24PM CDT
Major U.S. stock markets slide Wednesday amid poor Chinese economic data and a 14.5% month-over-month drop in U.S. new-home sales.
Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
Gilead's investors were wondering how long it would take for the company's newly launched hepatitis C drug Sovaldi to become a blockbuster; investors found out this week that the answer was less than one quarter. Sovaldi's sales totaled $2.3...
Stocks Trading Lower In Afternoon Action
at Investor's Business Daily - Wed Apr 23, 12:40PM CDT
Stocks were trading lower in early afternoon action Wednesday as the season for earnings reports hit full stride. The Nasdaq was down 0.6%, while the S&P 500 and the Dow Jones industrial average were off less than 0.1% each. Volume was running lower...
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.
Midday Glance: Biotechnology companies
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 11:00AM CDT
Gilead beat estimates on the back of strong Sovaldi sales.
Gilead, Illumina Q1 Earnings Win Wall Street's Love
at Investor's Business Daily - Wed Apr 23, 10:39AM CDT
Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead's $2.3 billion...
Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 10:30AM CDT
Cubist Pharma missed both on earnings and revenues.
Early Glance: Biotechnology companies
AP - Wed Apr 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...
Gilead (GILD) On Momo Momentum Watch Today
at The Street - Wed Apr 23, 8:49AM CDT
Trade-Ideas LLC identified Gilead (GILD) as a momo momentum candidate
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.
5 Stocks to Lose Post-Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:12AM CDT
It's a prudent move to identify companies in advance that are most likely to disappoint.